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We evaluated ABO associated outcomes in 1737 patients who underwent allogeneic hematopoietic cell
transplantation (allo-HCT) at Stanford University between January 1986 and July 2011. Grafts were 61% ABO
matched, 18% major mismatched (MM), 17% minor MM, and 4% bidirectional MM. Median follow-up was
6 years. In multivariate analysis, overall survival (OS) was inferior in minor MM hematopoietic cell
transplantations (median 2.1 versus 6.3 years; hazard ratio [HR], 1.56; 95% conﬁdence interval [CI], 1.19 to
2.05; P ¼ .001) in comparison with ABO-matched grafts. ABO minor MM was associated with an increase in
early nonrelapse mortality (NRM) (18% versus 13%; HR, 1.48; 95% CI, 1.06 to 2.06; P ¼ .02). In an independent
Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of 435 lymphoma patients
receiving mobilized peripheral blood grafts, impairment of OS (HR, 1.55; 95% CI, 1.07 to 2.25; P ¼ .021)
and increased NRM (HR, 1.72; 95% CI, 1.11 to 2.68; P ¼ .03) were observed in recipients of ABO minoreMM
grafts. A second independent analysis of a CIBMTR data set including 5179 patients with acute myeloid
leukemia and myelodysplastic syndrome identiﬁed a nonsigniﬁcant trend toward decreased OS in recipients
of ABO minoreMM grafts and also found ABO major MM to be signiﬁcantly associated with decreased OS (HR,
1.19; 95% CI, 1.08 to 1.31; P < .001) and increased NRM (HR, 1.23; 95% CI, 1.08 to 1.4; P ¼ .002). ABO minor and
major MM are risk factors for worse transplantation outcomes, although the associated hazards may not be
uniform across different transplantation populations. Further study is warranted to determine which patient
populations are at greatest risk, and whether this risk can be modiﬁed by antieB cell therapy or other peri-
transplantation treatments.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
In the setting of allogeneic hematopoietic cell trans-
plantation (allo-HCT) using bone marrow, peripheral blood,
or umbilical cord blood, adequate matching between human
leukocyte antigens (HLA) is considered to be the only abso-
lute requirement uponwhich to base donor selections. Otheredgments on page 753.
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ty for Blood and Marrow Transplantation.factors, such as donor age, gender, parity, ABO type, and
cytomegalovirus (CMV) serostatus, play a secondary role
when selecting between multiple HLA-compatible donors
[1,2]. The risk of ABO incompatibility between donors and
recipients, though of critical importance during solid organ
transplantation, has largely been considered negligible in
allo-HCT. This likely derives from a controversial body of
literature regarding the contribution of different types of
ABO mismatch (MM) to clinical outcomes in allo-HCT
patients (reviewed extensively by Rowley et al. [3]).
Because of microbial molecular mimicry with ABO anti-
gens, humans are almost uniformly immunized to whichever
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nomenon results in hemolytic transfusion reactions when
patients with pre-existing immunity and antibody titers
receive incompatible blood products. This scenario is equiva-
lent to ABO major MM in allo-HCT, a setting in which persis-
tence of recipient type anti-ABO antibodies may lead to severe
hemolysis of donor red cells and, in some cases, delayed
erythrocyte engraftment, red cell aplasia, or even graft failure
[3-11]. ABO minor MM, on the other hand, represents a sce-
nario unique to allo-HCT and solid organ transplantation and
occurs when donors possess anti-recipient ABO B lympho-
cytes and antibodies. Because adoptive transfer of such pas-
senger B lymphocytes into a host with abundant cognate
antigenmay lead to their further stimulation, this scenario has
been associatedwith hemolysis of recipient-derived erythroid
elements in the peri-transplantation period and has been
linked to decreased overall survival (OS) [12-15]. ABO antigens
are also widely expressed on vascular and lymphatic endo-
thelium, peri-vascular connective tissues, and bile duct
epithelium, so tissue targeting by adoptively transferred B
cells may extend beyond hematopoietic tissues [16,17].
We retrospectively evaluated the patient characteristics
and clinical outcomes of 1737 patients who underwent allo-
HCT at Stanford University Medical Center between January
1986 and July 2011. We observed that ABO minor MM was
associated with a signiﬁcant decrement in OS and an in-
crease in nonrelapse mortality (NRM). To corroborate our
ﬁndings, we requested the Center for International Bone and
Marrow Transplant Research (CIBMTR) re-evaluate data that
contributed to 2 existing publications that did not previously
evaluate the role of donor-recipient ABO matching.PATIENTS AND METHODS
PatientsdSingle Institution
A total of 1737 patients who underwent allo-HCT at Stanford University
or Lucille Packard Children’s Hospital between January 1986 and July 1, 2011,
and who provided informed consent for retrospective access to their re-
cords, were included in our analysis. Access to all records was in compliance
with and supervised by the Stanford University School of Medicine insti-
tutional review board. Diagnoses among this single-institution cohort
included acute myeloid leukemia (AML) and acute lymphoblastic leukemia,
myelodysplastic syndrome (MDS), chronic myelogenous leukemia, primary
myeloﬁbrosis, unspeciﬁed myeloproliferative disorders, chronic lympho-
cytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma,
mycosis fungoides, multiple myeloma, severe aplastic anemia, hemopha-
gocytic lymphohistiocytosis and other inherited and acquired cytopenias,
sickle cell anemia and other inherited hemoglobinopathies, Hurler syn-
drome and other inherited metabolic syndromes, Wiskott-Aldrich syn-
drome and other primary immune deﬁciency syndrome, osteopetrosis, renal
cell carcinoma, and systemic lupus erythematosus. Patient ages ranged from
birth to 74 years old.
Myeloablative (MA) conditioning regimens were comprised of those
based on high-dose chemotherapy (carmustine, cyclophosphamide, and
etoposide; busulfan and cyclophosphamide; busulfan, etoposide, and
cyclophosphamide; high-dose cyclophosphamide; melphalan, thiotepa,
and ﬂudrabine) or based on high-dose radiation with chemotherapy
(fractionated total body irradiation [FTBI] with cyclophosphamide; FTBI
with etoposide; FTBI with etoposide and cyclophosphamide; FTBI, cytar-
abine, and cyclophosphamide) with or without incorporation of immuno-
suppressive antibody therapy (eg, antithymocyte globulin [ATG] or
alemtuzumab).
Nonmyeloablative (NMA) regimens included those with nonablative-
dose chemotherapy alone (ﬂudarabine and cyclophosphamide; ﬂudar-
abine, carmustine, and melphalan) and those combining radiation with
cytotoxic immunosuppression or chemotherapy (FTBI with ﬂudarabine,
total lymphoid irradiation with ATG, electron beam therapy with total
lymphoid irradiation and ATG) with or without additional immunosup-
pressive antibody treatments. Grafts were derived from bone marrow or
granulocyte colonyestimulating factor (G-CSF)emobilized peripheral blood
stem cells (PBSC) apheresis products. Patients receiving cord blood, hap-
loidentical, or syngeneic grafts were excluded from analysis.Immunosuppressive regimens largely consisted of a calcineurin inhibi-
tor (either cyclosporine or tacrolimus) combined with either methotrexate
or other agents, including corticosteroids, mycophenolate mofetil, or siro-
limus. Immunosuppressive regimens were selected either as standard of
care or, in some cases, they were exploratory combinations evaluated in the
setting of clinical trials.
Donors and recipients underwent HLA typing by serology until 1998,
since when high-resolution molecular typing for HLA-A, -B, -C, -DRB1, and
-DRQ1 was performed. All donors and recipients were serologically tested
for presence of anti-CMV IgG to determine prior viral exposure, and at-
tempts were made to pair CMV-negative recipients with CMV-negative
donors. ABO typing was performed routinely to ensure safe blood trans-
fusion support during the peri-transplantation period. No speciﬁc condi-
tioning or immunosuppressive regimens were selected for any patient on
the basis of ABO incompatibility.
Patients d Multiple Institution (CIBMTRdRatanatharathorn et al.)
As a corroborating analysis, we reanalyzed an existing data set created
by the CIBMTR to study the effect of pretransplantation rituximab on sur-
vival and graft-versus-host disease (GVHD) [18]. This cohort consisted of 435
B cell NHL patients who underwent T cellereplete allo-HCT with G-
CSFemobilized peripheral blood from 1999 to 2004. Patients who had
received anti-CD52, antieT cell antibodies, or T celledepleted grafts were
excluded. A total of 179 of these patients received rituximab during the 6
months before HCT and 256 patients did not. The existing multivariate an-
alyses, which contributed to the Ratanatharathorn et al. [18] publication,
were updated to include ABO match, major MM, minor MM, and bidirec-
tional MM to test the hypothesis that ABO matching was independently
associated with transplantation outcomes.
Patients d Multiple Institution (CIBMTRdLuger et al.)
We also reanalyzed an existing CIBMTR data set addressing outcomes in
patients undergoing allo-HCT for AML and MDS [19]. The Luger et al. [19]
study focused on the relative efﬁcacy of MA (3731 patients) and NMA
(1448 patients) conditioning regimens. Deﬁnitions of regimen intensity
follow established guidelines [20] and can be found in the original publi-
cation [19]. All patients received T cellereplete grafts from mobilized pe-
ripheral blood or bone marrow. ABO match, major MM, minor MM, and
bidirectional MM were added as variables to test the hypothesis that ABO
matching was independently associated with transplantation outcomes.
Deﬁnition of Outcomes
Our primary outcomes of interest were OS and NRM. OS was deﬁned as
the number of days between graft infusion (day 0) and death from any cause.
NRM was deﬁned as death from any cause other than recurrence of the
disease for which the patient underwent allo-HCT. Event-free survival (EFS)
was deﬁned as the number of days between graft infusion and either relapse
or death from any cause. Acute GVHD grades 2 though 4 were graded
clinically according to the Glucksberg scale [21]. Clinical relapse was
determined according to accepted clinical criteria for each disease type.
Statistical Methods
Medians and ranges are reported for patient ages and time to events.
Percentages are reported for categorical variables. Probabilities of OS and
EFS were estimated using the Kaplan-Meier method [22]. For OS, death from
any cause was deﬁned as an event, with surviving patients censored at last
follow-up time from HCT date. For EFS analyses, either relapse or death was
deﬁned as an event, censoring surviving patients without relapse. The log-
rank test was used to compare survival curves. All univariate and multi-
variate analyses were performed using proportional hazards models to
calculate relative risks and their 95% conﬁdence intervals (CI) [23].
Cumulative incidence functions with competing risks [24] were used to
estimate the probabilities of relapse, NRM, NRM up to day 100, and acute
GVHD grades 2 to 4 or grades 3 and 4. Probabilities of relapse were esti-
mated with relapse as an event and NRM as a competing risk. For NRM and
NRM at day 100 estimations, nonrelapse death was an event, with relapse
being the competing risk. For NRM at day 100, the time horizon is 100 days
after HCTdevents up to day 100 are included, with all other observations
with at least 100 days of follow-up time censored at day 100.
For probabilities of acute GVHD grades 2 to 4 and grades 3 and 4, death
was the competing risk in the model. Because the longest time to acute
GVHD was 125 days in the Stanford patient cohort, nonevent observations
with at least 125 days of follow-up were censored at day 125. Cumulative
incidence curves were compared according to Fine and Gray [25].
Two multivariate analysis models were used to accommodate in-
teractions between graft type (bone marrow or peripheral blood) and ABO
minor MM observed in the Stanford cohort. In 1 analysis, a mixture model
was created to determine whether, for either graft type, any of the ABO MM
Table 1
Patient Characteristics
Variable Stanford CIBMTR
(Ratanatharathorn)
CIBMTR
(Luger)
No. of patients 1737 435 5179
Age, median
(range), yr
41 (0-73) 50 (22-70) 45 (18-70)
Age group
<21 392 (22) 0 208 (4)
21-39 472 (27) 77 (18) 1677 (32)
40-59 704 (41) 316 (73) 2791 (54)
60 168 (10) 42 (10) 503 (10)
Recipient gender
Female 733 (42) 145 (33) 2331 (45)
Male 1004 (58) 290 (67) 2848 (55)
Diagnosis
AML/MDS/CML 1184 (68) 0 5179 (100)
NHL/CLL 302 (17) 435 (100) 0
Other 251 (15) 0 0
Donor
Related 1303 (75) 330 (76) 2079 (40)
Unrelated 434 (25) 105 (24) 3100 (60)
Graft type
PB 997 (57) 435 (100) 2846 (55)
BM 727 (42) 0 2333 (45)
Unknown 13 (1) 0 0
Regimen
MA 1211 (70) 197 (45) 3731 (72)
Reduced-
intensity
526 (30) 238 (55) 1448 (28)
ABO
Matched 1053 (61) 240 (59) 2608 (50)
Minor MM 297 (17) 73 (18) 1084 (21)
Major MM 309 (18) 73 (18) 977 (19)
Bidirectional MM 78 (4) 22 (5) 311 (6)
Unknown 0 0 199 (4)
Donor/recipient gender
M/M 550 (32) 167 (38) 1832 (35)
M/F 431 (25) 78 (18) 1296 (25)
F/M 454 (26) 123 (28) 1016 (20)
F/F 302 (17) 64 (15) 1035 (20)
Donor/recipient CMV status
D neg/R neg 403 (23) 123 (28) 1317 (25)
D neg/R pos 338 (20) 94 (22) 1375 (27)
D pos/R neg 204 (12) 62 (14) 576 (11)
D pos/R pos 562 (32) 134 (31) 1735 (34)
Unknown 230 (13) 22 (5) 176 (3)
Primary immunosuppression
CSA  other 651 (37) 129 (30) 833 (16)
CSA þ MTX 
other
372 (21) 149 (34) 2804 (54)
FK  other 87 (5) 47 (11) 423 (8)
FK þ MTX 
other
175 (10) 103 (24) 1119 (22)
Other 136 (8) 7 (2) 0
Unknown 316 (18) 0 0
Transplantation era
1987-1997 446 (26) 0 w
1998-2004 499 (29) 435 (100) 5179 (100)
2005-July 1,
2011
792 (46) 0 0
Follow-up
survivors,
median (range),
yr
6.0 (.3-23.7) 4.3 (.25-7.3) 1 (.09-10.7)
CML indicates chronic myeloid leukemia; PB, peripheral blood; BM, bone
marrow; M, male; F, female; D, donor; neg, negative; R, recipient; pos,
positive; CSA, cyclosporine; MTX, methotrexate; FK, FK506/tacrolimus.
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tween graft type and ABO MM was represented by using interaction terms
as covariates in the Cox regression model for overall survival [26,27]. In the
second model, 8 composite variables were created to indicate all combina-
tions of graft source (bone marrow or peripheral blood) and ABO matching
status and interactions were tested for each ABO match status by pair-wise
comparison of hazard ratios (HR).RESULTS
Patient CharacteristicsdSingle Institution Study
(Stanford)
Characteristics of the 1737 patients undergoing allo-HCT
at Stanford University Medical Center between January
1986 and July 2011 are shown in Table 1. In this single-
institution cohort, 1053 (60.6%) patient-donor pairs were
ABO matched, 297 (17.1%) were ABO minor MM, 309 (17.8%)
were ABOmajor MM, and 78 (4.5%) were ABO bidirectionally
MM. Patient characteristics within each ABO compatibility
group are shown in Supplemental Table 1. Patients generally
ﬁt into 2 large categories by diagnosis: (1) leukemia group
(acute myeloid and lymphoid leukemias, MDS, and chronic
myelogenous leukemia), and (2) lymphoma group (NHL and
CLL), with a relatively small number of patients with other
diagnoses. Roughly 75% of patients received related donor
grafts, whereas the remaining 25% received grafts from un-
related adult donors. A total of 1211 (70%) underwent MA
conditioning, whereas 526 (30%) received reduced-intensity
conditioning. For statistical analyses, we divided treatment
eras into the following groups: (1) 1986 to 1997, (2) 1998 to
2004 (before the advent of bone marrow graft plasma
depletion), and (3) 2005 to July 1, 2011 (all grafts were
plasma depleted).
Clinical Outcomes with ABO Minor MM Allo-HCT
ABO minor MM between donor and recipient was
uniquely associated with a range of clinical events, including
premature death (Table 2). ABO major and bidirectional MM
were not signiﬁcantly associated with any survival end-
points. Across the entire group studied, the presence of ABO
minor MM between donor and recipient was associated with
signiﬁcantly decreased OS (P ¼ .005) (Figure 1A). To further
elucidate the characteristics of the patients and the clinical
outcomes associated with this ﬁnding, we assessed the
impact of ABO minor MM on NRM and acute GVHD. Patients
receiving ABO minor MM grafts had a signiﬁcantly higher
risk of NRM (overall univariate HR, 1.34; 95% CI, 1.06 to 1.69;
P ¼ .015) (Figure 1B, Table 2). Interestingly, this signiﬁcant
disparity in NRM was already apparent before day 100 (HR,
1.41; 95% CI,1.03 to 1.94; P¼ .033), but acute GVHD grade 2 to
4 was not signiﬁcantly different between the 2 groups (HR,
1.6; 95% CI, .96 to 1.64; P ¼ .094). As a result of increased
NRM, median OS was just 2.1 years in the ABO minor MM
recipients, whereas it was 6.3 years in the ABO-matched
recipients (Table 2).
Graft Source Effect on ABO Minor MM Allo-HCT
Although the majority of allografts for malignant condi-
tions at Stanford have been derived from G-CSF-mobilized
PBSC since roughly 2000, the outcomes of a substantial
number of bone marrow graft recipients, including 455 ABO-
matched and 119 ABO minoreMM sources, were included in
this retrospective analysis (Supplemental Table 2). Bone
marrow grafts were highly associated with the ABO minor
MM effect, with signiﬁcantly decreased OS (HR, 1.7; 95% CI,
1.3 to 2.2; P ¼ .0002) and EFS (HR, 1.6; 95% CI, 1.2 to 2.1; P ¼
.0005) and increased NRM (HR, 1.8; 95% CI, 1.3 to 2.5; P ¼
.0004). Among the bone marrow graft recipients, we also
observed that the NRM at day 100 was signiﬁcantly higher in
recipients of ABO minoreMM grafts (HR, 2.0; 95% CI, 1.3 to
3.0; P ¼ .001) and that there was an associated increase in
acute GVHD grades 2 to 4 (HR, 1.6; 95% CI, 1.1 to 2.4; P¼ .025)
and grades 3 and 4 (HR, 2.4; 95% CI, 1.4 to 4.1; P ¼ .001).
Peripheral blood grafts did not demonstrate a signiﬁcant
Table 2
Patient Outcomes with ABO-Matched or ABO-MM Grafts (All Diagnoses)
Event ABO Matched ABO Minor MM ABO Major MM ABO Bidir MM
Total patients 1053 297 305 78
OS median, yr 6.3 2.1 5.87 NR
No. of events 526 167 153 32
HR (CI) 1 1.27 (1.07-1.52) .98 (.82-1.18) .8 (.56-1.5)
P value e .005 .87 .22
EFS, median, yr 2.7 1.2 2.08 7.27
No. of events 606 183 180 37
HR (CI) 1 1.2 (1.02-1.42) 1.02 (.86-1.21) .8 (.57-1.11)
P value e .028 .81 .18
Relapse
No. of events 328 89 107 20
HR (CI) 1 1.09 (.86-1.37) 1.12 (.9-1.4) .78 (.5-1.23)
P value e .49 .3 .29
NRM, overall
No. of events 278 94 73 17
HR (CI) 1 1.34 (1.06-1.69) .89 (.69-1.15) .82 (.5-1.34)
P value e .015 .38 .42
NRM, d 100
Events at d 100 137 53 25 5
HR (CI) 1 1.41 (1.03-1.94) .62 (.4-.95) .48 (.2-1.18)
P value e .033 .027 .11
aGVHD, grade 2-4
Events at d 125 220 72 61 14
HR (CI) 1 1.26 (.96-1.64) .95 (.72-1.26) .87 (.51-1.49)
P value e .094 .73 .6
aGVHD, grade 3-4
Events at d 125 166 35 29 10
HR (CI) 1 1.14 (.78-1.67) .77 (.51-1.17) 1.22 (.64-2.3)
P value e .49 .23 .55
Bidir indicates bidirectional; aGVHD, acute GVHD.
Signiﬁcant associations are shown in bold text.
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grafts (Supplemental Table 2), and no other ABO in-
compatibilities were associated with signiﬁcant outcome
effects.
Multivariate Analyses of Single- and Multi-institution
Cohorts
The predominance of the ABO minor MM effect in bone
marrow grafts but not in peripheral blood grafts, as shown in
Supplemental Table 2, implies a differential effect based on
graft type. This interaction was accommodated in 2 multi-
variate approaches that included all patients. First, a mixture
model evaluating outcomes with bone marrow and periph-
eral blood grafts based on whether ABO minor MM was
present and accounting for other covariates listed in the
legend of Table 3 was employed. In this interaction model,
ABO minor MM remained a risk for decreased OS (HR, 1.56;
95% CI, 1.19 to 2.05; P ¼ .001) and increased NRM (HR, 1.48;
95% CI, 1.06 to 2.06; P ¼ .02) (Table 3). In the second model,
pair-wise comparisons of HR with 8 composite variable ac-
counting for all combinations of graft source and ABO
matching status showed that ABO minor MM with bone
marrow was associated with lower OS (P ¼ .001) and higher
NRM (P ¼ .02) than ABO-matched bone marrow. Among
peripheral blood recipients, all ABO MM combinations had
HR that were not signiﬁcantly different than the ABO-
matched group (OS, P > .80 and NRM, P > .40).
To better assess the risk of ABO MM in lymphoma pa-
tients, we analyzed an existing lymphoma patient data set
previously compiled by Ratanatharathorn et al. and the
CIBMTR for ABO effects [18]. Patients in this data set were all
diagnosed with B cell NHL and underwent T cellereplete
PBSC transplantation. When the original study was per-
formed, ABO compatibility was not included in themultivariate models. We, thus, re-evaluated this relatively
homogeneous patient population for the impact of ABO MM
on clinical outcomes. ABO status of both donor and recipient
was known for 408 patients, with 240 (59%) ABO matched,
73 (18%) minor MM, 73 (18%) major MM, and 22 (5%) bidi-
rectionally MM.
In Cox regression analysis, ABOminor MMwas associated
with impaired OS in comparison with ABO-matched pairs
(HR, 1.55; 95% CI, 1.07 to 2.25; P ¼ .021) (Figure 2A, Table 3).
ABO minor MM also was signiﬁcantly associated with
increased NRM (HR, 1.72; 95% CI, 1.11 to 2.68; P ¼ .016)
(Figure 2C, Table 3). ABO MM did not signiﬁcantly associate
with relapse, acute GVHD grades 2 to 4 or grades 3 and 4, or
chronic GVHD (data not shown).
To address ABO MM effects in patients with myeloid
diseases treated at multiple institutions, we also re-
evaluated an existing CIBMTR data set addressing the
outcome of 5179 patients allografted with MA or NMA
preparations for AML and MDS [19]. All types of ABO MM
exhibited a trend toward decreased OS in comparison with
ABO-matched grafts (Figure 2B), but only ABO major MM
was found to be signiﬁcantly associated with decreased OS
(HR, 1.19; 95% CI, 1.08 to 1.31; P < .001) and increased NRM
(HR, 1.23; 95% CI, 1.08 to 1.40; P ¼ .002) (Figure 2B,D). ABO
minor MM was not signiﬁcantly associated with changes in
OS (HR, 1.06; 95% CI, .97 to 1.16; P ¼ .24) or NRM (HR, 1.07;
95% CI, .94 to 1.21; P ¼ .33).
DISCUSSION
This study describes the effect of ABOMMon outcomes in
patients undergoing related and unrelated donor allo-HCT
for all indications at a single institution (Stanford Univer-
sity), and in 2 published CIBMTR registry studies that did not
previously account for ABO MM in multivariate models of
Figure 1. Recipient survival when donor was ABO matched, minor MM, major
MM, or bidirectionally MM. Recipients receiving minor-MM grafts experienced
a signiﬁcant overall survival impairment compared with those receiving ABO-
matched grafts (P ¼ .005) (A). Cumulative incidence of NRM was increased in
recipients of ABO minor MM grafts compared with recipients of ABO-matched
grafts (P ¼ .015) (B).
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1737 patients who underwent transplantation between 1986
and 2011, we identiﬁed a signiﬁcant impairment in OS
(univariate HR, 1.27; 95% CI, 1.07 to 1.52; P ¼ .005; multi-
variate HR, 1.56; 95% CI, 1.19 to 2.05; P ¼ .001) in patients
receiving ABO minoreMM grafts, whereas other forms of
ABO MM were not signiﬁcantly associated with outcome
(Figure 1A; Tables 2 and 3). The survival decrement in re-
cipients of ABOminoreMMgrafts is attributable to increased
NRM (univariate HR, 1.34; 95% CI, 1.06 to 1.69; P ¼ .015;
multivariate HR, 1.48; 95% CI, 1.06 to 2.06; P ¼ .02), with risk
of mortality evident before day 100 after transplantation. A
nonsigniﬁcant trend toward increased acute GVHD grades 2
to 4 was noted, but the pathophysiology of ABO minor
MMerelated events remains to be better elucidated.
In the Stanford analysis, we noted an interaction between
ABO minor MM and bone marrow grafts, which is consistent
with bone marrow having a higher relative fraction of B
lymphocytes adoptively transferred into recipients [28]. In
recipients of ABO minoreMM bone marrow grafts, an
increased risk of acute GVHD was observed (HR, 1.6; 95% CI,
1.1 to 2.4; P ¼ .025) (Supplemental Table 2). No form of ABO
incompatibility was associated with NRM or survival out-
comes in recipients of PBSC grafts at Stanford. Interestingly,
however, the CIBMTR (Ratanatharathorn et al. [18]) analysis
revealed increased risk of NRM (multivariate HR,1.72; 95% CI,1.11 to 2.68; P¼ .02) and decreased OS (multivariate HR,1.55;
95% CI,1.07 to 2.25; P¼ .021) with ABOminoreMMgrafts in a
relatively homogeneous cohort of lymphoma patients, all of
whom received PBSC grafts (Figure 2A,C), suggesting the
attributable risks of this form of ABO incompatibility may not
exclusively be present with marrow grafts. It is likely that
host features interact with adoptively transferred lympho-
cytes fromABOMMdonors inways that are not evident from
this study. It is also possible that the differences in risk with
ABO minoreMM PBSC grafts between Stanford and the
multi-institution Ratanatharathorn et al. [18] study could
potentially be related to differences in the composition or
handling of PBSC grafts, administered cell dose at different
institutions, or management of post-transplantation im-
mune suppression tapers. It is also possible that lymphoma
patients, being lymphopenic from lymphotoxic therapies
for their primary disease, may experience increased
post-transplantation homeostatic expansion of adoptively
transferred donor B cells, leading to enhanced activation of
relevant anti-ABO lymphocytes. This phenomenon might be
expected in patients who do not have residual bioactive rit-
uximab in vivo at the time of adoptive lymphocyte transfer
and reduced in patients treated with rituximab within 6
months before adoptive lymphocyte transfer.
Althoughwe identiﬁed NRM and OS risks with ABOminor
MM in both the Stanford and CIBMTR (Ratanatharathorn
et al. [18]) analyses, the same effect was not observed in the
CIBMTR (Luger et al. [19]) analysis of 5179 patients who
underwent transplantation at 223 centers in 37 different
countries [19] The Luger et al. [19] study included only pa-
tients with AML and MDS, but with a mixture of bone
marrow and PBSC grafts (2333 versus 2846) andMA and RIC/
NMA conditioning (3731 versus 1448). The reasons for the
difference in the impact of ABO minoreMM grafts in this
study in comparison with the other studies remain unclear,
but it is possible that the relatively low OS in this cohort (34%
for myeloablated recipients, 33% for reduced-intensity con-
ditioning, and 26% for NMA conditioning) affected the ability
to detect OS differences in ABO subsets. It is also possible that
management of other ABO incompatibilities differed across
this multi-institution cohort in comparison with Stanford
and the Ratanatharathorn et al. [18] study sites, leading to
lower relative importance of ABO minor MM. Instead, ABO
major mismatches were associated with worse survival and
higher NRM (Figure 2B,D).
Watz et al. recently reported an analysis of trans-
plantation outcomes in 310 patients undergoing reduced-
intensity conditioning and identiﬁed increased risk of NRM
in patients receiving ABO minoreMM allografts and meeting
criteria for passenger lymphocyte syndrome (PLS), deﬁned as
detection of donor type anti-ABO antibodies within 1 month
of transplantation [29]. In their study, 6 patients out of 66
with ABO minoreMM grafts met these criteria and their
survival was 0% versus 61% in patients without PLS (P <
.001); however, deaths weremore frequently associatedwith
relapse than NRM, and the generalizability of these data are
unclear because most of the patients experiencing PLS un-
derwent allo-HCT for solid tumors. None of the patients in
the cohorts we studied had available data regarding anti-
ABO antibody titers after transplantation, so we are unable
to explore the effect of such antibodies or their utility as
biomarkers of PLS. Nevertheless, measurement of donor type
anti-ABO antibodies during the early post-HCT period could
prove useful for better understanding the incidence of PLS
and whether objective markers of adoptively transferred
Table 3
Multivariate Cox Regression Analysis of ABO MM Effect on OS and NRM
Event ABO Matched ABO Minor MM ABO Major MM ABO Bidir MM
OS, Stanford*
No. evaluable 1049 293 309 78
HR (CI) 1 1.56 (1.19-2.05) 1.02 (.85-1.23) .87 (.61-1.26)
P value e .001 .82 .82
OS, CIBMTR (Ratanatharathorn)y
No. evaluable 240 73 73 22
HR (CI) 1 1.55 (1.07-2.25) .86 (.57-1.31) .94 (.37-2.39)
P value e .021 .49 .91
OS, CIBMTR (Luger)z
No. evaluable 2540 1065 955 308
HR (CI) 1 1.06 (.97-1.16) 1.19 (1.08-1.31) 1.13 (.97-1.31)
P value e .24 <.001 .11
NRM, Stanford*
No. evaluable 1049 293 309 78
HR (CI) 1 1.48 (1.06-2.06) .91 (.7-1.18) .94 (.57-1.55)
P value e .02 .47 .81
NRM, CIBMTR (Ratanatharathorn)y
No. evaluable 240 73 73 22
HR (CI) 1 1.72 (1.11-2.68) .87 (.52-1.46) 1.42 (.69-2.9)
P value e .02 .6 .34
NRM, CIBMTR (Luger)z
No. evaluable 2540 1065 955 308
HR (CI) 1 1.07 (.94-1.21) 1.23 (1.08-1.4) 1.11 (.9-1.36)
P value e .33 .002 .35
Signiﬁcant associations are shown in bold text.
* Variables included in the model are: ABO match (matched versus minor MM versus major MM versus bidirectional MM), diagnosis category (leukemia
versus lymphoma versus other), age at transplantation (20, 21 to 39, 40 to 59, 60), recipient gender (male versus female), donor relatedness (HLA-identical
sibling versus unrelated), graft type (PBSC versus bone marrow), indicator of joint ABOminor MM and PBSC, regimen type (MA versus NMA), transplantation era
(before 1998 versus 1998 to 2004 versus after 2004). The signiﬁcant covariates for overall survival were: diagnosis (lymphoma versus leukemia; HR, .71; 95% CI,
.58 to .87; P¼ .001) and (other versus leukemia; HR, .72; 95% CI, .57 to .92; P¼ .007), age at transplantation (20 versus60; HR, .51; 95% CI, .36 to .71; P< .0001)
and (21 to 39 versus60; HR, .57; 95% CI, .43 to .77; P¼ .0002), graft type (PBSC versus BM; HR, 2.0; 95% CI, 1.57 to 2.5; P< .0001), joint ABOminorMM and PBSC
indicator (1 versus 0, HR, .65; 95% CI, .46 to .92; P ¼ .014), regimen type (NMA versus MA; HR, .66; 95% CI, .53 to .83; P ¼ .0002), and transplantation era (before
1998 versus 1998 to 2004; HR, 1.29; 95% CI, 1.03 to 1.61; P ¼ .03) and (after 2004 versus 1998 to 2004; HR, .84; 95% CI, .71 to .99; P ¼ .04). The signiﬁcant
covariates for NRM were age at transplantation (20 versus 60; HR, .24; 95% CI, .15 to .42; P < .0001) and (21 to 39 versus 60; HR, .43; 95% CI, .27 to .68; P ¼
.0003), donor relatedness (unrelated versus HLA-identical sibling; HR, 1.36; 95% CI, 1.05 to 1.76; P¼ .02), graft type (PBSC versus BM; HR, 1.49; 95% CI, 1.1 to 2.01;
P¼ .01), regimen type (NMA versus MA; HR, .32; 95% CI, .23 to .46; P< .0001), and transplantation era (before 1998 versus 1998 to 2004; HR, 1.41; 95% CI, 1.06 to
1.88; P ¼ .02) and (after 2004 versus 1998 to 2004; HR, .71; 95% CI, .55 to .90; P ¼ .006).
y Variables included in CIBMTR analysis of Ratanatharathorn et al. data: ABO match (matched versus minor MM versus major MM versus bidirectional MM),
age at transplantation (21 to 40 versus 41 to 50 versus 51 to 70), gender (male versus female), performance status (<90 versus90), lymphoma histology (small
lymphocytic and follicular lymphoma versus diffuse large B cell versus mantle cell), disease status before transplantation (complete remission versus partial
remission versus sensitive relapse versus other relapse, ie, resistant/untreated/unknown/progressive disease), donor type (HLA-identical sibling versus unre-
lated donor), interval from diagnosis to transplantation, numbers of chemotherapy regimens received before transplantation (2 lines versus 3 to 6 lines versus
>6 lines), previous radiation (yes versus no), time from last dose of rituximab to transplantation (>6months or no prior treatment versus6months), number of
prior therapy with rituximab-containing regimens, conditioning regimens (MA versus NMA), GVHD prophylaxis (cyclosporin  others versus tacrolimus 
others), donor-recipient sex match (M>M versus M>F versus F>M versus F>F), donor parity (male donor versus nulliparous female donor versus parous female
donor versus others), donor-recipient CMV serology (/ versus others), year of transplantation (1999 to 2000 versus 2001 to 2004), and HLA match (HLA-
identical sibling versus well-matched versus partially matches/MM unrelated). Other signiﬁcant covariates are listed in the original Ratanatharathorn et al.
publication.
z Variables included in CIBMTR analysis of Luger et al. data: ABO match (matched versus minor MM versus major MM versus bidirectional MM), age at
transplantation, gender, Karnofsky performance score (<90 versus 90% versus unknown), disease (AML versus MDS), French-American-British subtype at
diagnosis (M0 to M2 versus M4 to M7 versus other/unclassiﬁed (for AML), refractory anemia or acquired idiopathic siderblastic anemia versus other MDS [for
MDS]), therapy-related leukemia (no versus yes versus unknown), cytogenetics (good versus intermediate versus poor prognosis versus unknown), blast
percentage at transplantation (<5% versus 5% to 10% versus >10% versus unknown), duration of ﬁrst complete remission (CR) for AML patients who underwent
transplantation in second CR (<6 versus 6 to 12 months versus unknown), disease status at transplantation (primary induction failure versus ﬁrst CR versus 
second CR versus relapse (for AML), treated versus untreated (for MDS)), time from remission to transplantation for AML patients who underwent trans-
plantation in ﬁrst CR (3 versus >3 months versus unknown), type of donor (HLA-identical sibling versus unrelated well-matched versus unrelated partially
matched versus unrelated MM versus unrelated matching unknown), donor age, donor-recipient sex match (F>M versus other), donor-recipient CMV serology
(/ versus  versus recipient þ versus unknown), graft type (BM versus PBSC), year of transplantation, previous autologous transplantation (no versus yes),
ATG (no versus yes), and GVHD prophylaxis (tacrolimus þ MTX  other versus tacrolimus  other versus CSA þ MTX  other versus CSA  other). Other
signiﬁcant covariates are listed in the original Luger et al. publication.
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sequelae of ABO minor MM grafts.
If donor type anti-ABO antibodies are pathogenic or
strongly correlate with PLS, a useful therapeutic maneuver
would be the administration rituximab or other antieB cell
therapy before transplantation to ablate adoptively trans-
ferred B lymphocytes.We attempted to evaluate the Stanford
data set for possible beneﬁcial effect from the administration
of rituximab within 6 months before allo-HCT; however, the
number of patients for whom this data was available waslimited. There was, nevertheless, a suggestion of possible
beneﬁt in 33 ABO minoreMM patients with NHL and CLL
patients who received rituximab within 6 months before
allo-HCT, with improved OS (HR, .4; 95% CI, .2 to .9; P ¼ .02)
and decreased NRM (HR, .3; 95% CI, .1 to .9; P ¼ .03) in
comparison with 19 NHL/CLL ABO minoreMM patients who
did not receive peri-HCT rituximab. Similarly, the CIBMTR
(Ratanatharathorn et al. [18]) study demonstrated decreased
OS in 44 recipients of ABO minoreMM PBSC grafts longer
than 6months after the last dose of rituximab (HR,1.6 versus
Figure 2. CIBMTR analysis of overall survival and cumulative incidence of NRM in patients receiving ABO-matched, minor MM, major MM, or bidirectionally (Bidir)
MM hematopoietic allografts for lymphoma (A and C; data from Ratanatharathorn et al. [18] evaluated for ABO effect) or AML/MDS (B and D; data from Luger et al.
[19] evaluated for ABO effect).
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the survival of 29 patients receiving ABO minoreMM grafts
within 6 months of last rituximab dose was not signiﬁcantly
different from that of patients receiving ABO-matched grafts
(HR, 1.44; 95% CI, .75 to 2.79; P ¼ .27). A complete analysis of
these outcomes in the Stanford and CIBMTR (Ratanathara-
thorn et al. [18]) data sets is not provided in this manuscript
because we are hesitant to make conclusions from these
small numbers of patients. We believe these preliminary
ﬁndings can only be considered hypothesis generating with
respect to a possible method for ameliorating the risk of ABO
minorMM in allo-HCT that deserves further study in a multi-
institution prospective study.
In our study, ABOmajorMMwas shown to be a signiﬁcant
hazard for increased NRM and decreased OS in the AML/MDS
CIBMTR (Luger et al. [19]) analysis, but not in the lymphoma
CIBMTR (Ratanatharathorn et al. [18]) study or the single-
institution Stanford study. It is possible the management of
ABO major MMeassociated hemolytic and red cell aplasia
events differed across the various study sites, leading
to the difference in HR. Hemolysis and red cell aplasia
resulting from recipient type anti-donor ABO antibodies
may be managed with supportive red blood cell transfusion
(conveying the risk of transfusional iron overload),
erythrocyte-stimulating agents (conveying the risk
of thrombosis), intravenous immune globulin, or manipula-
tions of immunosuppression that cannot be assessed from
registry data. The risk of hemolytic events may also be
modiﬁed by the quality of erythrocyte cross-matching
and avoidance of other red cell antigen-antibody in-
compatibilities. ABO major MM may also be associated with
delayed platelet engraftment, which may convey risks in
the post-HCT setting and increase NRM risk in some
populations [30].Watz et al. also presented a possible explanation for
deleterious effects in patients receiving ABO majoreMM al-
lografts [29]. Ninety-ﬁve of the 310 patients they studied
received ABO majoreMM grafts, and 12 of those patients
developed persistent or recurring recipient type anti-ABO
antibodies (PRABO). Patients with PRABO had signiﬁcantly
increased NRM (50% versus 21%, P ¼ .03) and decreased 3-
year OS (17% versus 73%, P ¼ .002) [29]. Interestingly, pa-
tients with PRABO had an increased incidence of hemolytic
anemia, which is to be expected, but a decreased incidence of
acute and chronic GVHD. Management of PRABO-associated
hemolysis was not detailed and the reasons for decreased
GVHD but higher NRM with lower OS remain uncertain, but
could be associated with the therapies used to treat sequelae
of ABO major MM or additional blood product support
and iron overload toxicity, or the ﬁnding may be spurious
given the small sample size. Again, though, routine post-
transplantation measurement of anti-ABO antibodies and
capture of such data in transplantation databases could
prove useful for better understanding the incidence of he-
molysis and other associated negative outcomes in ABO
major MM.
To our knowledge, the data we have presented here
represent 1 of the largest analyses of ABO incompatibility in
allo-HCT. Nevertheless, several other retrospective studies
have identiﬁed ABO minor and major MM as risks in the
setting of allo-HCT [31], and ours is not the ﬁrst study to ﬁnd
contradictory results when assessing the impact of ABO in-
compatibilities in different patient populations [3]. As with
other studies, a consistent and universal pattern for risks
associated with ABO incompatibility fails to emerge from our
study. Nevertheless, we identiﬁed risk for increased NRM
and decreased OS with ABO minor MM in 2 of the 3 cohorts
we studied, which adds to other studies that have identiﬁed
A.C. Logan et al. / Biol Blood Marrow Transplant 21 (2015) 746e754 753minorMM as a survival risk. ABOminorMMHCT provides an
attractive model for additional study of adoptive lymphocyte
transfer since activation of donor lymphocytes can be
measured by the titer of donor type anti-ABO antibodies, and
methods for reducing the production of such antibodies
exist, as discussed above. We conclude that systematic
measurement of anti-ABO antibodies after allo-HCT and
capture of such data in transplantation registries should be
pursued to enhance understanding of the kinetics of donor
lymphocyte activation and the clinical events associated
with anti-ABO antibodies in ABO incompatible allo-HCT.
Lastly, we conclude from this study that an ABO-matched
donor is preferable to an ABO-MM donor, when the option
exists.ACKNOWLEDGMENTS
The authors thank the nursing staff, social workers, case
managers, physical therapists, dieticians, and data managers
who made the care of the patients described herein possible.
The care of these patients and the management of data were
supported byNational Institutes of Health P01CA049605. The
authors also wish to acknowledge the critical contribution of
Dr. Karl Blume (1937 to 2013), who established robust data
collection at the beginning of the Stanford Blood andMarrow
Transplant program, thus enabling this research. The CIBMTR
is supported by Public Health Service Grant/Cooperative
Agreement U24-CA076518 from the National Cancer Insti-
tute, the National Heart, Lung, and Blood Institute, and the
National Institute of Allergy and Infectious Diseases; a grant/
cooperative agreement 5U10HL069294 from NHLBI and NCI;
a contract HHSH250201200016C with Health Resources and
Services Administration; 2 grants N00014-13-1-0039 and
N00014-14-1-0028 from the Ofﬁce of Naval Research; and
grants from Actinium Pharmaceuticals; Allos Therapeutics,
Inc.; Amgen, Inc.; anonymous donation to the Medical Col-
lege of Wisconsin; Ariad; Be the Match Foundation; Blue
Cross and Blue Shield Association; Celgene Corporation;
Chimerix, Inc.; Fred Hutchinson Cancer Research Center;
Fresenius-Biotech North America, Inc.; Gamida Cell Teva
Joint Venture Ltd.; Genentech, Inc.; Gentium SpA; Genzyme
Corporation; GlaxoSmithKline; Health Research, Inc. Roswell
Park Cancer Institute; HistoGenetics, Inc.; Incyte Corpora-
tion; Jeff Gordon Children’s Foundation; Kiadis Pharma; The
Leukemia and Lymphoma Society; Medac GmbH; The Med-
ical College of Wisconsin; Merck & Co, Inc.; Millennium: The
Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec,
Inc.; National Marrow Donor Program; Onyx Pharmaceuti-
cals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics,
Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.;
Remedy Informatics; Sanoﬁ US; Seattle Genetics; Sigma-Tau
Pharmaceuticals; Soligenix, Inc.; St. Baldrick’s Foundation;
StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft
Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharma-
ceuticals; TerumoBCT; Teva Neuroscience, Inc.; THERAKOS,
Inc.; University of Minnesota; University of Utah; and Well-
point, Inc. The views expressed in this article do not reﬂect
the ofﬁcial policy or position of the National Institute of
Health, the Department of the Navy, the Department of De-
fense, Health Resources and Services Administration or any
other agency of the US Government.
Financial disclosure: The authors have no relevant
disclosures.
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.SUPPLEMENTARY DATA
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.bbmt.2014.12.036.REFERENCES
1. Howard A, Fernandez-Vina MA, Appelbaum FR, et al. Recommenda-
tions for donor HLA assessment and matching for allogeneic stem cell
transplantation: consensus opinion of the Blood and Marrow Trans-
plant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant.
2015;21:4-7.
2. Confer DL, Abress LK, Navarro W, Madrigal A. Selection of adult unre-
lated hematopoietic stem cell donors: beyond HLA. Biol Blood Marrow
Transplant. 2010;16(1 Suppl):S8-S11.
3. Rowley SD, Donato ML, Bhattacharyya P. Red blood cell-incompatible
allogeneic hematopoietic progenitor cell transplantation. Bone
Marrow Transplant. 2011;46:1167-1185.
4. Benjamin RJ, Connors JM, McGurk S, et al. Prolonged erythroid aplasia
after major ABO-mismatched transplantation for chronic myelogenous
leukemia. Biol Blood Marrow Transplant. 1998;4:151-156.
5. Worel N, Greinix HT, Schneider B, et al. Regeneration of erythropoiesis
after related- and unrelated-donor BMT or peripheral blood HPC
transplantation: a major ABO mismatch means problems. Transfusion.
2000;40:543-550.
6. Seebach JD, Stussi G, Passweg JR, et al. ABO blood group barrier in
allogeneic bone marrow transplantation revisited. Biol Blood Marrow
Transplant. 2005;11:1006-1013.
7. Mueller RJ, Stussi G, Odermatt B, et al. Major ABO-incompatible he-
matopoietic stem cell transplantation: study of post-transplant pure
red cell aplasia and endothelial cell chimerism. Xenotransplantation.
2006;13:126-132.
8. Helbig G, Stella-Holowiecka B, Wojnar J, et al. Pure red-cell aplasia
following major and bi-directional ABO-incompatible allogeneic stem-
cell transplantation: recovery of donor-derived erythropoiesis after
long-term treatment using different therapeutic strategies. Ann Hem-
atol. 2007;86:677-683.
9. Blin N, Traineau R, Houssin S, et al. Impact of donor-recipient major
ABO mismatch on allogeneic transplantation outcome according to
stem cell source. Biol Blood Marrow Transplant. 2010;16:1315-1323.
10. Ozkurt ZN, Yegin ZA, Yenicesu I, et al. Impact of ABO-incompatible
donor on early and late outcome of hematopoietic stem cell trans-
plantation. Transplant Proc. 2009;41:3851-3858.
11. Remberger M, Watz E, Ringden O, et al. Major ABO blood group
mismatch increases the risk for graft failure after unrelated donor
hematopoietic stem cell transplantation. Biol Blood Marrow Transplant.
2007;13:675-682.
12. Hunt BJ, Yacoub M, Amin S, et al. Induction of red blood cell destruction
by graft-derived antibodies after minor ABO-mismatched heart and
lung transplantation. Transplantation. 1988;46:246-249.
13. Reed M, Yearsley M, Krugh D, Kennedy MS. Severe hemolysis due to
passenger lymphocyte syndrome after hematopoietic stem cell trans-
plantation from an HLA-matched related donor. Arch Pathol Lab Med.
2003;127:1366-1368.
14. Erker CG, Steins MB, Fischer RJ, et al. The inﬂuence of blood group
differences in allogeneic hematopoietic peripheral blood progenitor
cell transplantation. Transfusion. 2005;45:1382-1390.
15. Bolan CD, Childs RW, Procter JL, et al. Massive immune haemolysis
after allogeneic peripheral blood stem cell transplantation with minor
ABO incompatibility. Br J Haematol. 2001;112:787-795.
16. Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens.
APMIS. 2000;108:1-28.
17. Breimer ME, Molne J, Norden G, et al. Blood group A and B antigen
expression in human kidneys correlated to A1/A2/B, Lewis, and
secretor status. Transplantation. 2006;82:479-485.
18. Ratanatharathorn V, Logan B, Wang D, et al. Prior rituximab correlates
with less acute graft-versus-host disease and better survival in B-cell
lymphoma patients who received allogeneic peripheral blood stem cell
transplantation. Br J Haematol. 2009;145:816-824.
19. Luger SM, Ringden O, Zhang MJ, et al. Similar outcomes using mye-
loablative versus reduced-intensity allogeneic transplant preparative
regimens for AML or MDS. Bone Marrow Transplant. 2012;47:
203-211.
20. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning
regimen workshop: deﬁning the dose spectrum. Report of a workshop
convened by the center for international blood and marrow transplant
research. Biol Blood Marrow Transplant. 2009;15:367-369.
21. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-
versus-host disease in human recipients of marrow from HL-A-
matched sibling donors. Transplantation. 1974;18:295-304.
22. Kaplan EI, Meier P. Nonparametric estimation from incomplete
observation. J Am Statist Assoc. 1958;53:457-481.
23. Jeong JH, Fine JP. Parametric regression on cumulative incidence
function. Biostatistics. 2007;8:184-196.
A.C. Logan et al. / Biol Blood Marrow Transplant 21 (2015) 746e75475424. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure
probabilities in the presence of competing risks: new representations
of old estimators. Stat Med. 1999;18:695-706.
25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution
of a competing risk. J Am Statist Assoc. 1999;94:496-509.
26. Bartoff JL, Lai TL, Shih M. Sequential experimentation in clinical trials.
New York: Sringer; 2013.
27. Lai TL, Lavori PW, Shih MC. Sequential design of phase II-III cancer
trials. Stat Med. 2012;31:1944-1960.
28. Theilgaard-Monch K, Raaschou-Jensen K, Palm H, et al. Flow cytometric
assessment of lymphocyte subsets, lymphoid progenitors, and he-
matopoietic stem cells in allogeneic stem cell grafts. Bone Marrow
Transplant. 2001;28:1073-1082.29. Watz E, Remberger M, Ringden O, et al. Analysis of donor and
recipient ABO incompatibility and antibody-associated complica-
tions after allogeneic stem cell transplantation with reduced-
intensity conditioning. Biol Blood Marrow Transplant. 2014;20:
264-271.
30. Ramirez P, Brunstein CG, Miller B, et al. Delayed platelet recovery after
allogeneic transplantation: a predictor of increased treatment-related
mortality and poorer survival. Bone Marrow Transplant. 2011;46:
981-986.
31. Kimura F, Sato K, Kobayashi S, et al. Impact of AB0-blood group in-
compatibility on the outcome of recipients of bone marrow transplants
from unrelated donors in the Japan Marrow Donor Program. Haema-
tologica. 2008;93:1686-1693.
